Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
ACEACat. No. 1319 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: Arachidonyl-2'-chloroethylamide Chemical Name: N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide |
Biological Activity
Potent and highly selective CB1 receptor agonist (Ki = 1.4 nM). Displays >1400-fold selectivity over CB2 receptors. Active in vivo. Also available as part of the Cannabinoid CB1 Receptor Tocriset™.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Hillard et al (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J.Pharmacol.Exp.Ther. 289 1427. PMID: 10336536.
Pertwee (1999) Pharmacology of cannabinoid receptor ligands. Curr.Med.Chem. 6 635. PMID: 10469884.
Patel et al (2001) Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. 2001 Symposium on the Cannabinoids, International..
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: ACEA, supplier, Potent, selective, CB1, agonists, Cannabinoids, Receptors, cb1r
Quick Order
Find multiple products by catalog number
Pain Research Guide
Reserve your free copy
Highlights over 280 products for Pain research. Reserve copy
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Therapeutic Strategies in Schizophrenia
Written by J. Lieberman
'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.
New Products in this Area
Potent, high affinity CB1 receptor inverse agonist
SR 141716ASelective CB1 receptor antagonist
Tocris Events
Win a Kindle
11th Congress of the French Neuroscience Society
May 21 - 24, 2013
Lyon, France
Booth Number: 32